STUDY 1 DESIGN

Patients were adults aged ≥18 years and undergoing arthroscopic
subacromial decompression surgery under general anesthesia1

PATIENT RANDOMIZATION 2:1:1 (N=107)1

POSIMIR n=53 Vehicle Control n=25 Bupivacaine HCl 0.25% n=29 5 mL injection WITH 660 mg bupivacaine HCl* 20 mL injection WITH 50 mg bupivacaine HCl 5 mL injection WITHOUT bupivacaine HCl 500 mg or 1000 mg acetaminophen QID required for 72 hours post surgery Intravenous or oral morphine as needed or
Bupivacaine HCl 0.25% n=29 Vehicle Control n=25 POSIMIR n=53 20 mL injection WITH 50 mg bupivacaine HCl 5 mL injection WITHOUT bupivacaine HCl 5 mL injection WITH 660 mg bupivacaine HCl* 500 mg or 1000 mg acetaminophen QID required for 72 hours post surgery Intravenous or oral morphine as needed or

CO-PRIMARY OUTCOME:
Mean pain intensity on movement scores from
Time 0 through 72 hours and total opioid rescue analgesia from Time 0 through 72 hours

POSIMIR indication is based on safety and efficacy data from 3 clinical studies in shoulder
arthroscopy, predominantly arthroscopic subacromial decompression. Adequate
evidence of effectiveness was demonstrated in 1 of those 3 studies (Study 1).1

*Doses above 660 mg per patient have not been studied in clinical trials.1

Intravenous morphine provided until patients were able to tolerate oral morphine.1
HCl=hydrochloride; QID=four times a day.

PROVEN EFFICACY
WHILE IN THE PACU

POSIMIR patients averaged mild to moderate pain on movement and
only mild pain at rest through the first 6 hours post‑surgery in Study 1

Person with arms elevated at a 90-degree angle

MEAN PAIN INTENSITY ON MOVEMENT

(Based on a 1-10 Numerical Rating Scale)

Time (hours)POSIMIRVehicle Control
14.68.1
24.47.7
44.17.3
63.77.7
Person reclining in a chair

MEAN PAIN INTENSITY AT REST

(Based on a 1-10 Numerical Rating Scale)

Time (hours)POSIMIRVehicle Control
13.76.9
23.25.9
42.34.9
62.24.8

POSIMIR patients saw less of a need for opioid introduction while still under facility care

MEDIAN TIME TO FIRST USE OF
OPIOID RESCUE MEDICATION

POSIMIR 12.4 hours

Vehicle Control 1.2 hours

P=0.014

SIGNIFICANT PAIN RELIEF
FOR UP TO 72 HOURS

POSIMIR patients had a 20% reduction in pain on movement
while using 66% fewer opioids vs Vehicle Control in Study 1

Person with arms elevated at a 90-degree angle

MEAN PAIN INTENSITY ON
MOVEMENT FOR UP TO 72 HOURS

(Based on a 1-10 Numerical Rating Scale)

Mean pain intensity on movement for up to 72 hours post-surgery during POSIMIR® clinical trial
Person reclining in a chair

MEAN PAIN INTENSITY
AT REST FOR UP TO 72 HOURS

(Based on a 1-10 Numerical Rating Scale)

Mean pain intensity at rest for up to 72 hours post-surgery during POSIMIR® clinical trial

TOTAL USE OF OPIOID ANALGESIA
FROM TIME 0-72 HOURS

(median IV morphine mg equivalent)

POSIMIR 4.0 mg

Vehicle Control 12.0 mg

P=0.010

The outcomes of Study 2 and Study 3, both evaluating POSIMIR in arthroscopic shoulder surgery,
favored POSIMIR in analgesic and opioid-use endpoints over Vehicle Control, but did not reach
statistical significance.

40% OF POSIMIR PATIENTS DID NOT REQUIRE ANY
OPIOIDS THROUGH 72 HOURS POST-SURGERY IN STUDY 1

% OF PATIENTS NOT REQUIRING OPIOID RESCUE
MEDICATION, 0-72 HOURS

100 20 40 60 80 0 P =0.027 Proportion of patients % Vehicle Control (n=25) POSIMIR (n=53) 16% 40%

REQUEST A REPRESENTATIVE

A representative can discuss POSIMIR with you to review
administration instructions and respond to your questions.

INDICATIONS AND USAGE

POSIMIR is a bupivacaine solution indicated in adults for administration into the subacromial space under direct arthroscopic visualization to produce post-surgical analgesia for up to 72 hours following arthroscopic subacromial decompression.

IMPORTANT SAFETY INFORMATION

BOXED WARNING: RISK OF POTENTIAL ADVERSE EMBOLIC EFFECTS RESULTING FROM INADVERTENT INTRAVASCULAR INJECTION.